Global Antibody-oligonucleotide Conjugates (AOCs) Market Growth (Status and Outlook) 2026-2032

July 2026 | 89 pages | ID: GE89F63D1AD1EN
LP Information

Abstracts

The global Antibody-oligonucleotide Conjugates (AOCs) market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.

AOCs (Antibody-Oligonucleotide Conjugates) consist of three main components: a carrier (antibody), a linker, and a small nucleic acid. They allow for targeted delivery, combining the antibody?s ability to bind to specific cells with the gene-silencing capability of small nucleic acids, addressing the delivery challenges faced by conventional small nucleic acid drugs.

The development of Antibody-Oligonucleotide Conjugates (AOCs) aims to address the inherent limitations of small nucleic acids, such as poor serum stability, low membrane permeability, and lack of tissue selectivity. AOCs combine the longer half-life and precise targeting capabilities of antibodies with the gene-silencing power of small nucleic acids, achieving high-precision selectivity and effective delivery to target cells.

The global Antibody-oligonucleotide Conjugates (AOCs) market is experiencing explosive growth, with the core driving force coming from clinical breakthroughs in rare diseases (such as Duchenne muscular dystrophy and myotonic dystrophy) and innovative needs for targeted tumor therapy. Leading companies Avidity Biosciences (AOC 1001 clinical phase II) and Dyne Therapeutics (FORCE? platform) are leading the race. On the technical side, pH-sensitive linkers optimize oligonucleotide release and bispecific antibody design improves tissue penetration, but low lysosomal escape efficiency (<10%) and high large-scale production costs (single dose exceeds US$50,000) are still the main bottlenecks. Avidity has successfully concluded positive pre-BLA discussions with the FDA and has adjusted the BLA submission timeline to the first quarter of 2026, aiming to proceed via the U.S. Accelerated Approval pathway. AOC 1044 is expected to become the first commercialized AOC therapeutic. In the next 3-5 years, with more than 20 AOC pipelines entering the clinic (indications expanding to ophthalmology and CNS) and AI-driven conjugation design (such as generative AI-optimized antibody-oligonucleotide pairing) being implemented, this field is expected to replicate the successful path of ADC drugs and become the next tens of billions of dollars market for precision medicine.

This report presents a comprehensive overview, market shares, and growth opportunities of Antibody-oligonucleotide Conjugates (AOCs) market by product type, application, key players and key regions and countries.

Segmentation by Type:

• Site-specific Coupling
• Random Coupling

Segmentation by Antibody Format:

• Full-length IgG
• Fab
• scFv
• Nanbody/VHH
• Others

Segmentation by Application:

• Rare and Genetic Diseases
• Cancer Treatment
• Central Nervous System Disorders

This report also splits the market by region:

• United States
• China%li%
• Europe
• Other regions
• Japan
• South Korea
• Southeast Asia
• Rest of world

The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report:

• Avidity Biosciences
• Dyne Therapeutics
• Tallac Therapeutics
• Denali Therapeutics
• Gennao Bio
• ChainGen Bio

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Size 2026-2032
  2.1.2 Antibody-oligonucleotide Conjugates (AOCs) Market Size CAGR by Region
2.2 Antibody-oligonucleotide Conjugates (AOCs) Segment by Type
  2.2.1 Site-specific Coupling
  2.2.2 Random Coupling
  2.2.3 Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type
    2.2.3.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Market Share by Type (2026-2032)
    2.2.3.2 Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth Rate by Type (2026-2032)
2.3 Antibody-oligonucleotide Conjugates (AOCs) Segment by Antibody Format
  2.3.1 Full-length IgG
  2.3.2 Fab
  2.3.3 scFv
  2.3.4 Nanbody/VHH
  2.3.5 Others
  2.3.6 Antibody-oligonucleotide Conjugates (AOCs) Market Size by Antibody Format
    2.3.6.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Market Share by Antibody Format (2026-2032)
    2.3.6.2 Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth Rate by Antibody Format (2026-2032)
2.4 Antibody-oligonucleotide Conjugates (AOCs) Segment by Application
  2.4.1 Rare and Genetic Diseases
  2.4.2 Cancer Treatment
  2.4.3 Central Nervous System Disorders
  2.4.4 Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2032)
    2.4.4.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Market Share by Application (2026-2032)
    2.4.4.2 Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth Rate by Application (2026-2032)

3 ANTIBODY-OLIGONUCLEOTIDE CONJUGATES (AOCS) KEY PLAYERS

3.1 Date of Key Players Enter into Antibody-oligonucleotide Conjugates (AOCs)
3.2 Key Players Antibody-oligonucleotide Conjugates (AOCs) Product Offered
3.3 Key Players Antibody-oligonucleotide Conjugates (AOCs) Funding/Investment Analysis
3.4 Funding/Investment
  3.4.1 Funding/Investment by Regions
  3.4.2 Funding/Investment by End-Industry
3.5 Key Players Antibody-oligonucleotide Conjugates (AOCs) Valuation & Market Capitalization
3.6 Key Players Mergers & Acquisitions, Expansion Plans
3.7 Market Ranking
3.8 New Product/Technology Launches
3.9 Partnerships, Agreements, and Collaborations
3.10 Mergers and Acquisitions

4 ANTIBODY-OLIGONUCLEOTIDE CONJUGATES (AOCS) BY REGIONS

4.1 Antibody-oligonucleotide Conjugates (AOCs) Market Size by Regions (2026-2032)
4.2 United States Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth (2026-2032)
4.3 China Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth (2026-2032)
4.4 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth (2026-2032)
4.5 Rest of World Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth (2026-2032)

5 UNITED STATES

5.1 United States Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2032)
5.2 United States Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2032)

6 EUROPE

6.1 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2032)
6.2 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2032)

7 CHINA

7.1 China Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2032)
7.2 China Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2032)

8 REST OF WORLD

8.1 Rest of World Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2032)
8.2 Rest of World Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2032)
8.3 Japan
8.4 South Korea
8.5 Southeast Asia

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 KEY INVESTORS IN ANTIBODY-OLIGONUCLEOTIDE CONJUGATES (AOCS)

10.1 Company A
  10.1.1 Company A Company Details
  10.1.2 Company Description
  10.1.3 Companies Invested by Company A
  10.1.4 Company A Key Development and Market Layout
10.2 Company B
  10.2.1 Company B Company Details
  10.2.2 Company Description
  10.2.3 Companies Invested by Company B
  10.2.4 Company B Key Development and Market Layout
10.3 Company C
  10.3.1 Company C Company Details
  10.3.2 Company Description
  10.3.3 Companies Invested by Company C
  10.3.4 Company C Key Development and Market Layout
10.4 Company D
10.5 ??

11 KEY PLAYERS ANALYSIS

11.1 Avidity Biosciences
  11.1.1 Avidity Biosciences Company Details
  11.1.2 Avidity Biosciences Antibody-oligonucleotide Conjugates (AOCs) Product Offered
  11.1.3 Avidity Biosciences Antibody-oligonucleotide Conjugates (AOCs) Market Size (2025 VS 2031)
  11.1.4 Avidity Biosciences Main Business Overview
  11.1.5 Avidity Biosciences News
11.2 Dyne Therapeutics
  11.2.1 Dyne Therapeutics Company Details
  11.2.2 Dyne Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Product Offered
  11.2.3 Dyne Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Market Size (2025 VS 2031)
  11.2.4 Dyne Therapeutics Main Business Overview
  11.2.5 Dyne Therapeutics News
11.3 Tallac Therapeutics
  11.3.1 Tallac Therapeutics Company Details
  11.3.2 Tallac Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Product Offered
  11.3.3 Tallac Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Market Size (2025 VS 2031)
  11.3.4 Tallac Therapeutics Main Business Overview
  11.3.5 Tallac Therapeutics News
11.4 Denali Therapeutics
  11.4.1 Denali Therapeutics Company Details
  11.4.2 Denali Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Product Offered
  11.4.3 Denali Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Market Size (2025 VS 2031)
  11.4.4 Denali Therapeutics Main Business Overview
  11.4.5 Denali Therapeutics News
11.5 Gennao Bio
  11.5.1 Gennao Bio Company Details
  11.5.2 Gennao Bio Antibody-oligonucleotide Conjugates (AOCs) Product Offered
  11.5.3 Gennao Bio Antibody-oligonucleotide Conjugates (AOCs) Market Size (2025 VS 2031)
  11.5.4 Gennao Bio Main Business Overview
  11.5.5 Gennao Bio News
11.6 ChainGen Bio
  11.6.1 ChainGen Bio Company Details
  11.6.2 ChainGen Bio Antibody-oligonucleotide Conjugates (AOCs) Product Offered
  11.6.3 ChainGen Bio Antibody-oligonucleotide Conjugates (AOCs) Market Size (2025 VS 2031)
  11.6.4 ChainGen Bio Main Business Overview
  11.6.5 ChainGen Bio News

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Antibody-oligonucleotide Conjugates (AOCs) Market Size CAGR by Region (2026-2032) ($ millions)
Table 2. Major Players of Site-specific Coupling
Table 3. Major Players of Random Coupling
Table 4. Global Market Size by Type (2026-2032) ($ millions)
Table 5. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Market Share by Type (2026-2032)
Table 6. Major Players of Full-length IgG
Table 7. Major Players of Fab
Table 8. Major Players of scFv
Table 9. Major Players of Nanbody/VHH
Table 10. Major Players of Others
Table 11. Global Market Size by Antibody Format (2026-2032) ($ millions)
Table 12. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Market Share by Antibody Format (2026-2032)
Table 13. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2032) ($ millions)
Table 14. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Market Share by Application (2026-2032)
Table 15. Date of Global Key Players Enter into Antibody-oligonucleotide Conjugates (AOCs) Market
Table 16. Global Key Players Antibody-oligonucleotide Conjugates (AOCs) Product Offered
Table 17. Key Players Antibody-oligonucleotide Conjugates (AOCs) Funding/Investment (Million USD)
Table 18. Funding/Investment by Regions
Table 19. Funding/Investment by End-Industry
Table 20. Key Players Antibody-oligonucleotide Conjugates (AOCs) Valuation & Market Capitalization (Million USD)
Table 21. Key Players Mergers & Acquisitions, Expansion Plans
Table 22. Antibody-oligonucleotide Conjugates (AOCs) New Product/Technology Launches
Table 23. Antibody-oligonucleotide Conjugates (AOCs) Industry Partnerships, Agreements, and Collaborations
Table 24. Antibody-oligonucleotide Conjugates (AOCs) Industry Mergers and Acquisitions
Table 25. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Regions 2026-2032 ($ millions)
Table 26. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Market Share by Regions 2026-2032
Table 27. United States Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2032) ($ millions)
Table 28. United States Antibody-oligonucleotide Conjugates (AOCs) Market Size Market Share by Type (2026-2032)
Table 29. United States Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2032) ($ millions)
Table 30. United States Antibody-oligonucleotide Conjugates (AOCs) Market Size Market Share by Application (2026-2032)
Table 31. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2032) ($ millions)
Table 32. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size Market Share by Type (2026-2032)
Table 33. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2032) ($ millions)
Table 34. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size Market Share by Application (2026-2032)
Table 35. China Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2032) ($ millions)
Table 36. China Antibody-oligonucleotide Conjugates (AOCs) Market Size Market Share by Type (2026-2032)
Table 37. China Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2032) ($ millions)
Table 38. China Antibody-oligonucleotide Conjugates (AOCs) Market Size Market Share by Application (2026-2032)
Table 39. Rest of World Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2032) ($ millions)
Table 40. Rest of World Antibody-oligonucleotide Conjugates (AOCs) Market Size Market Share by Type (2026-2032)
Table 41. Rest of World Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2032) ($ millions)
Table 42. Rest of World Antibody-oligonucleotide Conjugates (AOCs) Market Size Market Share by Application (2026-2032)
Table 43. Key Market Drivers & Growth Opportunities of Antibody-oligonucleotide Conjugates (AOCs)
Table 44. Key Market Challenges & Risks of Antibody-oligonucleotide Conjugates (AOCs)
Table 45. Key Industry Trends of Antibody-oligonucleotide Conjugates (AOCs)
Table 46. Company A Company Details
Table 47. Companies Invested by Company A
Table 48. Company A Key Development and Market Layout
Table 49. Company B Company Details
Table 50. Companies Invested by Company B
Table 51. Company B Key Development and Market Layout
Table 52. Company C Company Details
Table 53. Companies Invested by Company C
Table 54. Company C Key Development and Market Layout
Table 55. Avidity Biosciences Basic Information, Head Office, Major Market Areas and Its Competitors
Table 56. Avidity Biosciences Antibody-oligonucleotide Conjugates (AOCs) Market Size (2025 VS 2031)
Table 57. Dyne Therapeutics Basic Information, Head Office, Major Market Areas and Its Competitors
Table 58. Dyne Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Market Size (2025 VS 2031)
Table 59. Tallac Therapeutics Basic Information, Head Office, Major Market Areas and Its Competitors
Table 60. Tallac Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Market Size (2025 VS 2031)
Table 61. Denali Therapeutics Basic Information, Head Office, Major Market Areas and Its Competitors
Table 62. Denali Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Market Size (2025 VS 2031)
Table 63. Gennao Bio Basic Information, Head Office, Major Market Areas and Its Competitors
Table 64. Gennao Bio Antibody-oligonucleotide Conjugates (AOCs) Market Size (2025 VS 2031)
Table 65. ChainGen Bio Basic Information, Head Office, Major Market Areas and Its Competitors
Table 66. ChainGen Bio Antibody-oligonucleotide Conjugates (AOCs) Market Size (2025 VS 2031)

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Antibody-oligonucleotide Conjugates (AOCs)
Figure 2. Antibody-oligonucleotide Conjugates (AOCs) Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth Rate 2026-2032 ($ millions)
Figure 7. Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region (2025 & 2032) ($ millions)
Figure 8. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Market Share by Type (2026-2032)
Figure 9. Global Site-specific Coupling Market Size Growth Rate
Figure 10. Global Random Coupling Market Size Growth Rate
Figure 11. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Market Share by Antibody Format (2026-2032)
Figure 12. Global Full-length IgG Market Size Growth Rate
Figure 13. Global Fab Market Size Growth Rate
Figure 14. Antibody-oligonucleotide Conjugates (AOCs) in Rare and Genetic Diseases
Figure 15. Global Antibody-oligonucleotide Conjugates (AOCs) Market: Rare and Genetic Diseases (2026-2032) ($ millions)
Figure 16. Antibody-oligonucleotide Conjugates (AOCs) in Cancer Treatment
Figure 17. Global Antibody-oligonucleotide Conjugates (AOCs) Market: Cancer Treatment (2026-2032) ($ millions)
Figure 18. Antibody-oligonucleotide Conjugates (AOCs) in Central Nervous System Disorders
Figure 19. Global Antibody-oligonucleotide Conjugates (AOCs) Market: Central Nervous System Disorders (2026-2032) ($ millions)
Figure 20. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Market Share by Application (2026-2032)
Figure 21. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size in Rare and Genetic Diseases Growth Rate
Figure 22. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size in Cancer Treatment Growth Rate
Figure 23. Funding/Investment
Figure 24. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Market Share by Regions 2026-2032
Figure 25. United States Antibody-oligonucleotide Conjugates (AOCs) Market Size 2026-2032 ($ millions)
Figure 26. China Antibody-oligonucleotide Conjugates (AOCs) Market Size 2026-2032 ($ millions)
Figure 27. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size 2026-2032 ($ millions)
Figure 28. Rest of World Antibody-oligonucleotide Conjugates (AOCs) Market Size 2026-2032 ($ millions)
Figure 29. United States Antibody-oligonucleotide Conjugates (AOCs) Consumption Market Share by Type in 2030
Figure 30. United States Antibody-oligonucleotide Conjugates (AOCs) Market Size Market Share by Application in 2030
Figure 31. Europe Antibody-oligonucleotide Conjugates (AOCs) Consumption Market Share by Type in 2030
Figure 32. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size Market Share by Application in 2030
Figure 33. China Antibody-oligonucleotide Conjugates (AOCs) Consumption Market Share by Type in 2030
Figure 34. China Antibody-oligonucleotide Conjugates (AOCs) Market Size Market Share by Application in 2030
Figure 35. Rest of World Antibody-oligonucleotide Conjugates (AOCs) Consumption Market Share by Type in 2030
Figure 36. Rest of World Antibody-oligonucleotide Conjugates (AOCs) Market Size Market Share by Application in 2030